Opsoclonus-myoclonus syndrome (OMS) is a rare autoimmune condition that usually affects young children. Most children with OMS are diagnosed at around 18 months of age. OMS affects one out of every 5 million children worldwide, and is slightly more common in girls than boys.
In OMS, a small tumor in the body (called a neuroblastoma) or a viral infection triggers the immune system to attack the nervous system. The symptoms of OMS usually begin abruptly and can include rapid, repeated eye movements (opsoclonus or “dancing eyes”), jerking movements (myoclonus), and loss of balance (ataxia). OMS may be initially diagnosed as acute cerebellar ataxia.
Most patients with OMS improve with standard immunotherapy treatment, though the relapse rate in children is 50 to 75 percent. Aggressive, early treatment appears to lower the rate of relapse and improve outcomes.